Reference
- Daar ES. Virology and immunology of acute HIV type 1 infection. AIDS Res Human Retroviruses 1998; 14(Suppl 3): S229–34
- Vanhems P, Allard R, Cooper DA, et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive? Clin Infect Dis 1997; 24(5): 965–70 [Erratum, Clin Infect Dis 1997; 25(2):352]
- Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125(4): 257–64 [Erratum, Ann Intern Med 1997; 126(2):174]
- Bollinger RC, Brookmeyer RS, Mehendale SM, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 1997; 278(23):2085–9
- Niu MT, Bethel J, Holodniy M, et al, and the DATRI 001 Study Group. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1998; 178(1):80–91
- Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med 1999; 130(1): 37–9
- Jacquez JA, Koopman JS, Simon CP, et al. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7(11): 1169–84
- Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282(12):1142–9
- Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997: 278(5341): 1295–300
- Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68(9):6103–10
- Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122(8):573–9
- Musey L, Highes J, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337(18): 1267–74
- Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-l-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278(5342): 1447–50
- Rosenberg ES. Preserving HIV-1 specific T-cell help: will it prevent progression? (Session 90) Proceedings, 6th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 Jan 31- Feb 4- Available at: http://www.retroconference.org/99. Accessed 2000 Feb 22
- Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5(5):518–25
- Carpenter CC, Cooper DA, Fischi MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283(3):381–90
- Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333(7):408–13 [Erratum, N Engl J Med 1995, 333(20):1367]
- Dalod M, Harzic M, Pellegrin I, et al. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 1998; 178(1): 61–9
- Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. (Letter) N Engl J Med 1999; 340(21): 1682–4
- Daar ES, Bai J, Hausner MA, et al. Acute HIV syndrome following discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med 1998; 128(10): 827–9